Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:33:38 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:PCRX - PACIRA BIOSCIENCES INC - https://www.pacira.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PCRX - Q2.015.00·22.790.121.00+0.643.1746.515,2806,97120.61  21.07  20.43527.985  18.8017:43:42Jan 2815 min RT 2¢

Recent Trades - Last 10 of 6971
Time ETExPriceChangeVolume
17:43:42Q21.000.64205,497
16:09:32Q20.600.242
16:09:10Q21.000.6416,736
16:04:53Q21.000.641
16:04:52Q21.000.641
16:04:45Q21.000.641
16:04:14Q21.000.641
16:04:14Q21.000.641
16:02:21Q21.000.64171
16:02:11Q21.000.64456

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-28 08:00U:PCRXNews ReleasePacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
2026-01-13 08:00U:PCRXNews ReleasePacira Announces Agreement with LG Chem to Make EXPAREL(TM) Available in Select Asian-Pacific Markets
2026-01-08 16:01U:PCRXNews ReleasePacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
2026-01-07 08:00U:PCRXNews ReleasePacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
2025-12-30 10:41U:PCRXNews ReleaseDOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
2025-12-18 08:00U:PCRXNews ReleasePacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
2025-12-03 08:00U:PCRXNews ReleasePacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-12-02 08:00U:PCRXNews ReleasePacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With ioveradegree Compared to Radiofrequency Ablation in Chronic Low Back Pain
2025-11-26 16:01U:PCRXNews ReleasePacira BioSciences Files EXPAREL(TM) Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
2025-11-11 08:00U:PCRXNews ReleasePacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
2025-11-10 20:09U:PCRXNews ReleaseDOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
2025-11-06 16:01U:PCRXNews ReleasePacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
2025-11-05 08:00U:PCRXNews ReleasePacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
2025-11-04 07:00U:PCRXNews ReleasePacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
2025-10-30 08:00U:PCRXNews ReleasePacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
2025-10-28 08:00U:PCRXNews ReleasePacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
2025-10-27 08:00U:PCRXNews ReleasePacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL(TM)
2025-10-23 08:00U:PCRXNews ReleasePacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL(TM)
2025-10-21 08:30U:PCRXNews ReleasePacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL(TM)
2025-10-20 16:01U:PCRXNews ReleasePacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy